In conclusion, FLT3-positive acute myeloid leukemia remains an extremely aggressive disease that requires timely treatment and the optimization of the use of new drugs at our disposal to minimize the emergence of resistance. This evidence concerns the gene FLT3 and acute myeloid leukemia.